XLO Earnings

Quarterly EPS
$-2.82
Q4 2024
$-2.49
Q1 2025
$-2.30
Q2 2025
$-1.58
Q3 2025
$0.95
Q4 2025
$-0.58
Q1 2026
$-0.33
Q2 2026
$-0.30
Q3 2026
Latest Revenue10.0M
Latest Net Income-5948000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q3 2026-$0.3010.0M-5948000-47.6%+81.0%
Q2 2026-$0.3318.7M-6373000+131.2%+85.7%
Q1 2026-$0.5812.6M-9529000+331.7%+76.7%
Q4 2025$0.9513.7M10.4M+693.9%+133.7%
Q3 2025-$1.5819.1M-16287000+742.5%+48.7%
Q2 2025-$2.308.1M-15844000+243.0%+31.5%
Q1 2025-$2.492.9M-13265000—+71.3%
Q4 2024-$2.821.7M-13093000—+68.6%
Q3 2024-$3.082.3M-14020000——
Q2 2024-$3.362.4M-13925000——
Q1 2024-$8.680-17203000——
Q4 2023-$8.970-17655000——
Xilio Therapeutics (XLO) — Earnings